| Acambis (Cambridge, UK and Cambridge, MA, USA) | Typhoid (marketed) and smallpox (marketed), yellow fever, Japanese encephalitis, West Nile, Dengue, Clostridium difficile | Vaccinia vaccines, live viral vectors attenuated by recombinant technology and vaccines using inactivated bacterial toxins | Development and manufacture of vaccines. Partnered with Baxter Healthcare for distribution |
| http://www.acambis.com/ | | | |
| Alphavax (Research Triangle Park, NC, USA) | HIV (phase 1), cytomegalovirus, influenza, SARS and three biodefense targets, Marburg virus, viral encephalitis and botulinum toxins | Live viral vectors based on alphavirus replicon expressing viral or bacterial antigens | Development of vaccine delivery systems. Some company funded, others grant funded, others partner funded. Partnered with Wyeth for herpes simplex virus, HPV, flu and respiratory syncytial virus |
| http://www.alphavax.com/home/ | | | |
| Bavarian Nordic | Smallpox, HIV, Japanese encephalitis, Dengue and measles | Live viral modified vaccinia Ankara (MVA) vectors | Development and manufacture vaccines. Partnered with GSK for smallpox, IDM Pharma for HIV vaccines, Impfstoffwerk Dessau-Tornau GmbH for manufacturing |
| http://www.bavarian-nordic.com/ | | | |
| Berna Biotech | Marketed: influenza, typhoid, hepatitis A and hepatitis B. Under development: hepatitis B (phase 3), yellow fever (phase 3), Pseudomonas aeruginosa (phase 3) | Virosome-based technology (liposomes containing viral capsid components) for antigen presentation, live virus/bacteria attenuated by recombinant technology as well as a recombinant subunit vaccine | Development and manufacture of vaccines. Partnered with Corixa, Orphan Europe, Chiron and Solvay |
| http://www.bernabiotech.com/ | | | |
| Bioport (Lansing, MI, USA), a subsidiary of Emergent BioSolutions (Gaitherburg, MD, USA) | Anthrax | Aluminum hydroxide–adsorbed cell-free vaccine prepared from Bacillus anthracis strain V770-NP1-R | Manufacture and supply US government stock-pile of only FDA-approved anthrax vaccine |
| http://www.bioport.com/default.asp | | | |
| Cambridge Biostability (Cambridge, UK) | Enterotoxic Escherichia coli | Technology for stabilizing vaccines in sugar glass and suspension in fluorocarbon liquids | Vaccine formulation and delivery. Partnered with Acambis |
| http://www.biostability.com/ | | | |
| CSL (Parkville, Australia) | Diphtheria with tetanus vaccine, (marketed),Q Vax (Coxiella burnetii vaccine, marketed) Tet-Tox (Tetanus vaccine, marketed) Fluvax (influenza vaccine, egg-based, trivalent, marketed) Plagues vaccine (Yersinia pestis marketed); HPV (Phase 3, licensed to Merck) HCV (Phase 2, licensed to Chiron) | Iscomatrix adjuvant, Virus-like particles | Licensed vaccines to Merck & Chiron, distribution partner for Merck & Chiron |
| DynPort Vaccine Company (Frederick, MD, USA) | Botulism, plague, tularemia and Venezuelan equine encephalitis | Live-attenuated vaccines, recombinant subunit vaccines and vaccine delivery systems | Subcontracts vaccine programs to research centers and companies. Partnered with Avant and Baxter and The National Institute of Allergy and Infectious Diseases |
| http://www.csc.com/mms/dvc/en/ | | | |
| ID Biomedical (Vancouver, BC) | Influenza, Neisseria meningitides, pneumococcal disease and group A streptococcus infections | Combination nasal delivery system and adjuvant made from nanospheres of bacterial proteins; recombinant subunit vaccines | Development of vaccines |
| http://www.idbiomed.com/ | | | Acquired by GSK |
| Intercell (Vienna) | Japanese encephalitis virus (phase 3) and hepatitis C (phase 2), streptococcal hospital-acquired infections and tuberculosis | Recombinant protein vaccines and synthetic adjuvant combining an anti-microbial peptide, and an immunostimulant oligodeoxynucleotide | Vaccines and other immunotherapies as well as antigen/epitope identification/validation services. Partnered with Merck |
| http://www.intercell.com/ | | | |
| Iomai (Gaithersburg, Maryland, USA) | Transcutaneous vaccination two influenza vaccines (phases 1 and 2), traveler's diarrhea (phase 2) and anthrax (phase 1) | Needle-free, transcutaneous vaccination using cholera toxin or heat-labile enterotoxin as adjuvants. | Development of vaccines |
| http://www.iomai.com/ | | | |
| Nobilon (Boxmeer, The Netherlands) part of the Akzo Nobel Pharma Group | Influenza, traveler's diarrhea, sexually transmitted diseases | Biofermentation expertise | Contract manufacture of vaccines. Works with other Akzo companies: Intervet (animal vaccines), Organon (human pharmaceutical production). Partnered with BioDiem for flu vaccine |
| http://www.nobilonvaccines.com/ | | | |
| VaxGen (Brisbane, CA, USA) | Anthrax, smallpox and bacterial meningitis | Recombinant subunit vaccines with alum-adjuvant as well as vaccinia vaccine | Development and manufacture of biodefense vaccines with facilities in California and South Korea. Partnered with Celltrion Incheon (South Korea) to build production facilities |
| http://www.vaxgen.com/ | | | |
